MerryLife Reports Positive Phase 1 Data for Oral Alzheimer’s Drug TML-6

MerryLife Reports Positive Phase 1 Data for Oral Alzheimer’s Drug TML-6

By, Admin 10 February 2026

MerryLife Biomedical Inc. announced positive Phase 1 results for TML-6, its investigational oral therapy for Alzheimer’s disease (AD).

The study showed good tolerability and a favourable safety profile, supporting continued clinical development.

Why TML-6 Is Different?

TML-6 is designed to modulate the autolysosomal system, a core cellular network involved in:

  • Protein clearance
  • Neuroinflammation
  • Oxidative stress
  • Aging-related neuronal dysfunction

Disruption of these pathways is increasingly linked to Alzheimer’s and Parkinson’s disease progression. Rather than targeting a single mechanism, TML-6 takes a multi-pathway approach.

Phase 2 Program: What’s Planned

Based on Phase 1 results, MerryLife plans a global Phase 2 study in early Alzheimer’s disease.

Key details:

  • ~210 participants
  • Patients with mild cognitive impairment and mild dementia
  • Trial sites in the US, Sweden, and Taiwan
  • Focus on safety, tolerability, and disease-relevant biomarkers

The program is expected to begin in early Alzheimer’s disease, where intervention may have greater impact.

Parkinson’s Disease Also in Focus

MerryLife is also evaluating TML-6 in Parkinson’s disease, where overlapping mechanisms drive neurodegeneration.

Additional preclinical data and development updates will be presented at:

  • AD/PD™ 2026 International Conference
  • March 19, 2026
  • Copenhagen

What the Company Says?

“Neurodegenerative diseases arise from interconnected biological processes, TML-6’s multi-targeted, oral approach supports earlier intervention in diseases with major unmet need.”

  • Dr. Ih-Jen Su, CEO of MerryLife Biomedical.

About TML-6

  • First-in-class, orally administered investigational therapy
  • Targets autolysosomal and aging-related pathways
  • Designed for chronic neurodegenerative conditions

Big Picture Takeaway

TML-6 positions MerryLife in a post-single-target Alzheimer’s narrative. If Phase 2 biomarker signals align with safety, this could validate multi-pathway modulation as a viable CNS strategy.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!